drugset / Trial / NCT06863701

Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis

NCT06863701

Phase 3 Recruiting 72 enrolled Laboratorios Silanes S.A. de C.V.
RandomizedParallel-groupDouble-blindTreatment

Summary

Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the Fixed-Dose Combination of Etoricoxib/Betamethasone Versus Etoricoxib in Patients With Acute Gouty Arthritis

Timeline

Start
2025-01-27
Primary completion
2026-12-31
Completion
2027-01-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Betamethasone Other / unclassified 0.25 mg Oral
Comparator Etoricoxib Small molecule 90 mg Oral

Indications